compared to nicotine replacement therapy (NRT) – up from moderate-certainty in the September 2021...
+6017-9906976
9AM - 5PM MON-FRI
9AM - 5PM MON-FRI
A new tool to aid smoking cessation and nicotine dependence
Exclusive distributor in Malaysia of the Nicovape® Q range of NVP products
January 2024’s Cochrane Collaboration states that:
“there is high-certainty evidence that NVPs increase quit rates compared to nicotine replacement therapy (NRT) and moderate-certainty evidence that they increase quit rates compared to vaping products without nicotine”.
NVPs may be particularly useful for patients who have a history of failed quit attempts using other therapies.
Australia is the first country to establish a therapeutic access pathway to vaping to for smoking cessation.
Nicovape® Q is the first, and remains the only, NVP distributed exclusively under medical prescription globally.
Prescribers have used Nicovape® Q to help thousands of patients stop smoking and vaping permanently.
Liber’s Nicovape® Q offers prescribers an NVP that:
For patients with a history of failed attempts to stop smoking, the therapeutic use of NVPs, particularly when coupled with ongoing support, shows great promise.
compared to nicotine replacement therapy (NRT) – up from moderate-certainty in the September 2021...
Obelia seized more than 35 tonnes of vaping products in October, comprising 376,000...